Aegerion Pharmaceuticals (AEGR) Scheduled to Post Earnings on Tuesday
Aegerion Pharmaceuticals (NASDAQ:AEGR) will post its Q214 quarterly earnings results on Tuesday, July 29th. Analysts expect Aegerion Pharmaceuticals to post earnings of ($0.41) per share and revenue of $35.40 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last released its earnings data on Tuesday, May 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.10. The company had revenue of $27.00 million for the quarter, compared to the consensus estimate of $33.58 million. On average, analysts expect Aegerion Pharmaceuticals to post $-0.94 EPS for the current fiscal year and $2.16 EPS for the next fiscal year.
Aegerion Pharmaceuticals (NASDAQ:AEGR) traded down 3.43% during mid-day trading on Monday, hitting $28.97. 233,939 shares of the company’s stock traded hands. Aegerion Pharmaceuticals has a 52 week low of $26.25 and a 52 week high of $101.00. The stock has a 50-day moving average of $31.46 and a 200-day moving average of $44.85. The company’s market cap is $854.1 million.
AEGR has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Aegerion Pharmaceuticals in a research note on Wednesday, July 16th. They now have a $29.00 price target on the stock. On a related note, analysts at Goldman Sachs initiated coverage on shares of Aegerion Pharmaceuticals in a research note on Tuesday, May 27th. They set a “sell” rating and a $27.00 price target on the stock. Finally, analysts at Citigroup Inc. downgraded shares of Aegerion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $71.10.
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.